The cytochrome P450 inhibitor SKF-525A disrupts autophagy in primary rat hepatocytes

Chemico-Biological Interactions

Volumn 255, Issue , 2016, Pages 55-62

  Luo, Yong ^a   Yang, Xi ^a   Shi, Qiang ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

Autophagy; Cytochrome P450; Hepatocyte; Hepatotoxicity; SKF 525A

Indexed keywords

1 AMINOBENZOTRIAZOLE; ALPHA NAPHTHOFLAVONE; CYTOCHROME P450; GREEN FLUORESCENT PROTEIN; KETOCONAZOLE; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; METYRAPONE; MICROTUBULE ASSOCIATED PROTEIN; MICROTUBULE ASSOCIATED PROTEIN LIGHT CHAIN 3 II; PROADIFEN; PROTEIN P62; TICLOPIDINE; UNCLASSIFIED DRUG; CYTOCHROME P450 INHIBITOR; LC3 PROTEIN, RAT; PROTEASOME;

ANIMAL CELL; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; BIOACCUMULATION; CELL INTERACTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; IMMUNOFLUORESCENCE; LIVER CELL; LIVER TOXICITY; LYSOSOME; MALE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN LOCALIZATION; PROTEIN METABOLISM; PROTEIN TRANSPORT; QUANTITATIVE ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; TOXICOLOGICAL PARAMETERS; WESTERN BLOTTING; ANIMAL; CELL CULTURE; DRUG EFFECTS; MEMBRANE FUSION; METABOLISM; PATHOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; AUTOPHAGOSOMES; AUTOPHAGY; CELLS, CULTURED; CYTOCHROME P-450 ENZYME INHIBITORS; HEPATOCYTES; LYSOSOMES; MALE; MEMBRANE FUSION; MICROTUBULE-ASSOCIATED PROTEINS; PROADIFEN; PROTEASOME ENDOPEPTIDASE COMPLEX; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84960172392     PISSN: 00092797     EISSN: 18727786     Source Type: Journal    
DOI: 10.1016/j.cbi.2016.03.007     Document Type: Article

References (27)

1. [1] Franklin, M.R., Hathaway, L.B., 2-Diethylaminoethyl-2,2-diphenylvalerate-HCl (SKF525A) revisited: comparative cytochrome P450 inhibition in human liver microsomes by SKF525A, its metabolites, and SKF-acid and SKF-alcohol. Drug Metab. Dispos. 36:12 (2008), 2539–2546.
2. [2] Yang, K.H., et al. Effects of cytochrome P450 inducers and inhibitors on the pharmacokinetics of intravenous furosemide in rats: involvement of CYP2C11, 2E1, 3A1 and 3A2 in furosemide metabolism. J. Pharm. Pharmacol. 61:1 (2009), 47–54.
3. [3] Henderson, M.C., et al. Metabolism of the anti-tuberculosis drug ethionamide by mouse and human FMO1, FMO2 and FMO3 and mouse and human lung microsomes. Toxicol. Appl. Pharmacol. 233:3 (2008), 420–427.
4. [4] Ahmad, M., Study on cytochrome p-450 dependent retinoic acid metabolism and its inhibitors as potential agents for cancer therapy. Sci. Pharm. 79:4 (2011), 921–935.
5. [5] Maioli, M.A., et al. The role of mitochondria and biotransformation in abamectin-induced cytotoxicity in isolated rat hepatocytes. Toxicol. Vitro 27:2 (2013), 570–579.
6. [6] Shi, Q., et al. Hepatic cytochrome P450s attenuate the cytotoxicity induced by leflunomide and its active metabolite A77 1726 in primary cultured rat hepatocytes. Toxicol. Sci. 122:2 (2011), 579–586.
7. [7] Lee, S.K., et al. Role of metabolism in 1-bromopropane-induced hepatotoxicity in mice. J. Toxicol. Environ. Health A 73:21–22 (2010), 1431–1440.
8. [8] Somchit, N., et al. Involvement of phenobarbital and SKF 525A in the hepatotoxicity of antifungal drugs itraconazole and fluconazole in rats. Drug Chem. Toxicol. 29:3 (2006), 237–253.
9. [9] Shi, Q., Greenhaw, J., Salminen, W.F., Inhibition of cytochrome P450s enhances (+)-usnic acid cytotoxicity in primary cultured rat hepatocytes. J. Appl. Toxicol. 34:8 (2014), 835–840.
10. [10] Capozzi, M.E., McCollum, G.W., Penn, J.S., The role of cytochrome P450 epoxygenases in retinal angiogenesis. Investig. Ophthalmol. Vis. Sci. 55:7 (2014), 4253–4260.
11. [11] Iqbal, J., et al. Smoke carcinogens cause bone loss through the aryl hydrocarbon receptor and induction of Cyp1 enzymes. Proc. Natl. Acad. Sci. U. S. A. 110:27 (2013), 11115–11120.
12. [12] Martinkova, M., Kubickova, B., Stiborova, M., Effects of cytochrome P450 inhibitors on peroxidase activity. Neuro Endocrinol. Lett. 33:Suppl. 3 (2012), 33–40.
13. [13] Ni, H.M., et al. Activation of autophagy protects against acetaminophen-induced hepatotoxicity. Hepatology 55:1 (2012), 222–232.
14. [14] Apostolova, N., et al. Compromising mitochondrial function with the antiretroviral drug efavirenz induces cell survival-promoting autophagy. Hepatology 54:3 (2011), 1009–1019.
15. [15] Weng, Z., et al. Regorafenib impairs mitochondrial functions, activates AMP-activated protein kinase, induces autophagy, and causes rat hepatocyte necrosis. Toxicology 327 (2015), 10–21.
16. [16] Galluzzi, L., et al. Metabolic control of autophagy. Cell 159:6 (2014), 1263–1276.
17. [17] Acharya, P., et al. Liver cytochrome P450 3A endoplasmic reticulum-associated degradation: a major role for the p97 AAA ATPase in cytochrome P450 3A extraction into the cytosol. J. Biol. Chem. 286:5 (2011), 3815–3828.
18. [18] Aki, T., et al. Impairment of autophagy: from hereditary disorder to drug intoxication. Toxicology 311:3 (2013), 205–215.
19. [19] Klionsky, D.J., et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 8:4 (2012), 445–544.
20. [20] Bystrom, J., et al. Inducible CYP2J2 and its product 11,12-EET promotes bacterial phagocytosis: a role for CYP2J2 deficiency in the pathogenesis of Crohn's disease?. PLoS One, 8(9), 2013, e75107.
21. [21] Hinson, J.A., Roberts, D.W., James, L.P., Mechanisms of acetaminophen-induced liver necrosis. Handb. Exp. Pharmacol. 196 (2010), 369–405.
22. [22] Mitchell, J.R., et al. Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism. J. Pharmacol. Exp. Ther. 187:1 (1973), 185–194.
23. [23] Ding, W.X., Yin, X.M., Analyzing macroautophagy in hepatocytes and the liver. Methods Enzymol. 453 (2009), 397–416.
24. [24] Jendzelovsky, R., et al. Inhibition of GSK-3beta reverses the pro-apoptotic effect of proadifen (SKF-525A) in HT-29 colon adenocarcinoma cells. Toxicol. Vitro 26:6 (2012), 775–782.
25. [25] FDA, Guidance for Industry Drug Interaction Studies—Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations. 2012.
26. [26] FDA, Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. 2014.
27. [27] Shi, Q., Yang, X., Mendrick, D.L., Hopes and challenges in using miRNAs as translational biomarkers for drug-induced liver injury. Biomark. Med. 7:2 (2013), 307–315.